|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SULF1 |
Gene summary for SULF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SULF1 | Gene ID | 23213 |
| Gene name | sulfatase 1 | |
| Gene Alias | SULF-1 | |
| Cytomap | 8q13.2-q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R809 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23213 | SULF1 | P5T-E | Human | Esophagus | ESCC | 5.50e-12 | 8.80e-01 | 0.1327 |
| 23213 | SULF1 | P8T-E | Human | Esophagus | ESCC | 4.26e-12 | 3.53e-01 | 0.0889 |
| 23213 | SULF1 | P9T-E | Human | Esophagus | ESCC | 4.33e-07 | 7.88e-01 | 0.1131 |
| 23213 | SULF1 | P10T-E | Human | Esophagus | ESCC | 1.63e-05 | 4.11e-01 | 0.116 |
| 23213 | SULF1 | P12T-E | Human | Esophagus | ESCC | 7.88e-29 | 7.95e-01 | 0.1122 |
| 23213 | SULF1 | P15T-E | Human | Esophagus | ESCC | 4.99e-13 | 7.28e-01 | 0.1149 |
| 23213 | SULF1 | P23T-E | Human | Esophagus | ESCC | 2.71e-02 | 4.23e-01 | 0.108 |
| 23213 | SULF1 | P26T-E | Human | Esophagus | ESCC | 2.58e-15 | 6.21e-01 | 0.1276 |
| 23213 | SULF1 | P27T-E | Human | Esophagus | ESCC | 3.52e-11 | 3.92e-01 | 0.1055 |
| 23213 | SULF1 | P30T-E | Human | Esophagus | ESCC | 2.71e-09 | 8.09e-01 | 0.137 |
| 23213 | SULF1 | P32T-E | Human | Esophagus | ESCC | 7.52e-07 | 4.92e-01 | 0.1666 |
| 23213 | SULF1 | P40T-E | Human | Esophagus | ESCC | 1.75e-03 | 3.79e-01 | 0.109 |
| 23213 | SULF1 | P44T-E | Human | Esophagus | ESCC | 1.05e-03 | 1.20e+00 | 0.1096 |
| 23213 | SULF1 | P47T-E | Human | Esophagus | ESCC | 2.97e-03 | 7.23e-01 | 0.1067 |
| 23213 | SULF1 | P48T-E | Human | Esophagus | ESCC | 3.10e-08 | 2.92e-01 | 0.0959 |
| 23213 | SULF1 | P54T-E | Human | Esophagus | ESCC | 1.35e-11 | 5.74e-01 | 0.0975 |
| 23213 | SULF1 | P62T-E | Human | Esophagus | ESCC | 3.59e-09 | 1.35e-01 | 0.1302 |
| 23213 | SULF1 | P74T-E | Human | Esophagus | ESCC | 1.90e-20 | 7.63e-01 | 0.1479 |
| 23213 | SULF1 | P76T-E | Human | Esophagus | ESCC | 2.25e-03 | 2.67e-01 | 0.1207 |
| 23213 | SULF1 | RNA-P17T-P17T-2 | Human | Lung | IAC | 1.69e-06 | 9.03e-01 | 0.3371 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
| GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
| GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
| GO:00163316 | Esophagus | ESCC | morphogenesis of embryonic epithelium | 98/8552 | 147/18723 | 2.12e-07 | 3.27e-06 | 98 |
| GO:0061458110 | Esophagus | ESCC | reproductive system development | 247/8552 | 427/18723 | 2.24e-07 | 3.42e-06 | 247 |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:004860818 | Esophagus | ESCC | reproductive structure development | 245/8552 | 424/18723 | 2.82e-07 | 4.14e-06 | 245 |
| GO:003011117 | Esophagus | ESCC | regulation of Wnt signaling pathway | 194/8552 | 328/18723 | 5.39e-07 | 7.14e-06 | 194 |
| GO:002261216 | Esophagus | ESCC | gland morphogenesis | 78/8552 | 118/18723 | 5.83e-06 | 6.03e-05 | 78 |
| GO:00301984 | Esophagus | ESCC | extracellular matrix organization | 171/8552 | 301/18723 | 6.08e-05 | 4.67e-04 | 171 |
| GO:003017716 | Esophagus | ESCC | positive regulation of Wnt signaling pathway | 87/8552 | 140/18723 | 6.18e-05 | 4.73e-04 | 87 |
| GO:00430624 | Esophagus | ESCC | extracellular structure organization | 171/8552 | 302/18723 | 7.73e-05 | 5.76e-04 | 171 |
| GO:00452294 | Esophagus | ESCC | external encapsulating structure organization | 172/8552 | 304/18723 | 7.80e-05 | 5.80e-04 | 172 |
| GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
| GO:000717810 | Esophagus | ESCC | transmembrane receptor protein serine/threonine kinase signaling pathway | 195/8552 | 355/18723 | 2.58e-04 | 1.58e-03 | 195 |
| GO:00308506 | Esophagus | ESCC | prostate gland development | 32/8552 | 45/18723 | 4.87e-04 | 2.70e-03 | 32 |
| GO:005067817 | Esophagus | ESCC | regulation of epithelial cell proliferation | 206/8552 | 381/18723 | 5.51e-04 | 3.02e-03 | 206 |
| GO:00603485 | Esophagus | ESCC | bone development | 115/8552 | 205/18723 | 1.67e-03 | 7.72e-03 | 115 |
| GO:000181916 | Esophagus | ESCC | positive regulation of cytokine production | 244/8552 | 467/18723 | 2.29e-03 | 1.01e-02 | 244 |
| GO:0006029 | Esophagus | ESCC | proteoglycan metabolic process | 48/8552 | 79/18723 | 4.93e-03 | 1.89e-02 | 48 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SULF1 | SNV | Missense_Mutation | c.1681N>A | p.Glu561Lys | p.E561K | Q8IWU6 | protein_coding | tolerated(0.3) | benign(0.32) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| SULF1 | SNV | Missense_Mutation | c.1457N>A | p.Arg486Gln | p.R486Q | Q8IWU6 | protein_coding | tolerated(0.14) | benign(0.221) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SULF1 | SNV | Missense_Mutation | c.2291N>A | p.Ser764Tyr | p.S764Y | Q8IWU6 | protein_coding | deleterious(0) | possibly_damaging(0.641) | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | |
| SULF1 | SNV | Missense_Mutation | c.2157C>A | p.Asn719Lys | p.N719K | Q8IWU6 | protein_coding | tolerated(0.85) | benign(0.007) | TCGA-C8-A133-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| SULF1 | SNV | Missense_Mutation | c.436N>A | p.Glu146Lys | p.E146K | Q8IWU6 | protein_coding | tolerated(0.08) | possibly_damaging(0.557) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
| SULF1 | insertion | In_Frame_Ins | novel | c.1468_1469insACGGGCTTGAAGGAT | p.Arg490delinsHisGlyLeuGluGlyTrp | p.R490delinsHGLEGW | Q8IWU6 | protein_coding | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| SULF1 | insertion | Frame_Shift_Ins | novel | c.320_321insG | p.Asn108GlnfsTer15 | p.N108Qfs*15 | Q8IWU6 | protein_coding | TCGA-AN-A0FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SULF1 | insertion | Frame_Shift_Ins | novel | c.321_322insTGCACTTTGCT | p.Asn108CysfsTer59 | p.N108Cfs*59 | Q8IWU6 | protein_coding | TCGA-AN-A0FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SULF1 | SNV | Missense_Mutation | novel | c.380N>T | p.Ala127Val | p.A127V | Q8IWU6 | protein_coding | deleterious(0) | benign(0.18) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SULF1 | SNV | Missense_Mutation | c.2575N>A | p.Asp859Asn | p.D859N | Q8IWU6 | protein_coding | tolerated_low_confidence(0.16) | benign(0.138) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |